Universität zu Köln

Schmitz, Ann Kristin, Sorg, Ruediger, V, Stoffels, Gabriele, Grauer, Oliver M., Galldiks, Norbert ORCID: 0000-0002-2485-1796, Steiger, Hans-Jakob, Kamp, Marcel A., Langen, Karl-Josef ORCID: 0000-0003-1101-5075, Sabel, Michael and Rapp, Marion . Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (F-18-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. Br. J. Neurosurg.. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1360-046X

Full text not available from this repository.

Abstract

Objective: Vaccination therapy using tumour antigen-loaded, autologous dendritic cells (DC) is a promising therapeutic approach alongside standard treatment for glioblastoma (GBM). However, reliable diagnostic criteria regarding therapy monitoring are not established. Here, we analysed the impact of additional F-18-fluoroethyl-tyrosine positron emission tomography (F-18-FET PET) imaging following DC vaccination therapy. Methods: We analysed data of GBM patients who received DC vaccination therapy. Following MRI diagnosis of tumour recurrence, additional static and dynamic F-18-FET PET imaging was performed. Vaccination was performed five times by intradermal injections, either weekly between concomitant radio/-chemotherapy and intermittent chemotherapy or after tumour recurrence, before re-radiation therapy. MRI and F-18-FET PET results were compared and correlated with clinical data. Results: Between 2003 and 2016, 5 patients were identified who received DC vaccination and F-18-FET PET imaging (1 female/4 males; mean age: 44 +/- 14 y). 3/5 patients showed congruent results of tumour progression. In three patients F-18-FET PET indicated treatment related changes, which was in contrast to MRI findings that indicated tumour progression. In these patients F-18-FET PET results could be confirmed by either neuropathological diagnosis or according to the RANO criteria Conclusions: Despite the small patients number our results indicate an additional impact of F-18-FET PET for monitoring outcome following vaccination therapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schmitz, Ann Kristin UNSPECIFIED UNSPECIFIED UNSPECIFIED Sorg, Ruediger, V UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoffels, Gabriele UNSPECIFIED UNSPECIFIED UNSPECIFIED Grauer, Oliver M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Galldiks, Norbert UNSPECIFIED orcid.org/0000-0002-2485-1796 UNSPECIFIED Steiger, Hans-Jakob UNSPECIFIED UNSPECIFIED UNSPECIFIED Kamp, Marcel A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Langen, Karl-Josef UNSPECIFIED orcid.org/0000-0003-1101-5075 UNSPECIFIED Sabel, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Rapp, Marion UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-144454
DOI:	10.1080/02688697.2019.1639615
Journal or Publication Title:	Br. J. Neurosurg.
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1360-046X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MALIGNANT GLIOMA; O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET; TEMOZOLOMIDE; SURGERY Multiple languages Clinical Neurology; Surgery Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14445